Physician profile
Martin Mccarter
NPI 1275627507
$17,120.02
in general payments reported to CMS, 2019-2025
8 companies · $2,685 in 2025
The $2,685 reported for 2025 was more than what 84% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,675 · 2020: $63.72 · 2022: $90.54 · 2023: $5,490 · 2024: $116 · 2025: $2,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,490 · Honoraria: $2,400 · Food and Beverage: $375 · Travel and Lodging: $26.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,490.00 |
| Honoraria | $2,400.00 |
| Food and Beverage | $374.80 |
| Travel and Lodging | $26.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,738.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $5,490.00 | 2023 | Keytruda |
| Iovance Biotherapeutics, INC. | $2,571.20 | 2025 | Amtagvi |
| Aadi Bioscience, INC. | $116.17 | 2024 | Fyarro |
| Astrazeneca Pharmaceuticals LP | $113.58 | 2025 | |
| Boston Scientific Corporation | $90.54 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Mccarter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.